Abstract

Aims: Dasotraline is a novel dopamine norepinephrine reuptake inhibitor currently being investigated in clinical studies for the treatment of ADHD at doses up to 8 mg/d. It was hypothesized that dasotraline would be characterized by minimal subjective reinforcing effects based on potent inhibition of norepinephrine reuptake and its pharmacokinetics of slow absorption/elimination in humans. This study evaluated the abuse potential of dasotraline compared to placebo and methylphenidate. Methods: Recreational stimulant users (N= 48) who had specific experience with cocaine, and who were able to distinguish methylphenidate (60 mg) versus placebo in a qualification session, were randomized to a 6-period, double-blind, crossover treatment phase. Treatment phase consisted of placebo, methylphenidate (40 mg, 80 mg), and dasotraline (8 mg, 16 mg, 36 mg). Subjective measures were evaluated over 72 h postdose. The primary endpoint was Emax on the Drug Liking Visual Analog Scale (VAS). Results: All 3 doses of dasotraline were not significantly different when compared to placebo on the primary (Drug Liking VAS) and most secondary endpoints. Methylphenidate significantly increased Drug Liking (VAS Emax, p < 0.001), supporting the validity of the study and sensitivity of the measures for detecting abuse-related effects. The 8mg and 16mg doses of dasotraline were associated with a similar incidence of adverse events (AEs) as placebo. A greater number of AEs and negative subjective effects (VAS Emin, p < 0.004 vs. placebo) were observed at 36mg dasotraline. Among potentially abuse-related AEs, incidence with dasotraline was lower than with methylphenidate. Conclusions: These results suggest that dasotraline has minimal abuse potential and is unlikely to be recreationally abused. Dasotraline is an investigational agent being evaluated for the treatment of ADHD, which presents a novel pharmacologic and pharmacokinetic profile.

Cite

CITATION STYLE

APA

K.S., K., S.S., H., K., S., N., S., N., L.-C., K., S., & A., L. (2015). Assessment of human abuse potential of dasotraline compared to methylphenidate and placebo in recreational stimulant users. Drug and Alcohol Dependence, 156, e115. https://doi.org/10.1016/j.drugalcdep.2015.07.319 LK  - http://rug.on.worldcat.org/atoztitles/link/?sid=EMBASE&issn=03768716&id=doi:10.1016%2Fj.drugalcdep.2015.07.319&atitle=Assessment+of+human+abuse+potential+of+dasotraline+compared+to+methylphenidate+and+placebo+in+recreational+stimulant+users&stitle=Drug+Alcohol+Depend.&title=Drug+and+Alcohol+Dependence&volume=156&issue=&spage=e115&epage=&aulast=Koblan&aufirst=Kenneth+S.&auinit=K.S.&aufull=Koblan+K.S.&coden=&isbn=&pages=e115-&date=2015&auinit1=K&auinitm=S

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free